Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with arthritis: experimental drug enters final testing phase

NCT ID NCT06869551

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study tests a drug called deucravacitinib in children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. The trial aims to see if the drug can control the disease and prevent flare-ups. About 60 participants will receive either the drug or a placebo, and researchers will monitor safety and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucravacitinib
What this could lead to
If successful, this could provide a new treatment option for children with juvenile psoriatic arthritis who haven't responded to other medications.
What could go wrong
This is a relatively small trial (60 participants), and the drug may not work better than placebo or could cause side effects. Results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). * Participants must have at least three joints that are affected by arthritis. * Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria * Participants must not have been diagnosed with JPsA before 5 years of age. * Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, * Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis psoriasis-related juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile psoriatic arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    33 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Meyer IRCCS

    RECRUITING

    Florence, Tuscany, 50139, Italy

  • Centro de Oncologia Leonardo Da Vinci - ATO Terapias

    RECRUITING

    Fortaleza, Ceará, 60140-025, Brazil

  • Children's Hospital of Fudan University

    RECRUITING

    Shanghai, 201102, China

  • Childrens Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Fakultni nemocnice Olomouc

    RECRUITING

    Olomouc, Olomouc Region, 779 00, Czechia

  • Fakultni nemocnice v Motole

    RECRUITING

    Prague, Praha 5, 150 06, Czechia

  • Guangzhou Women and Children's Medical Center

    RECRUITING

    Guangzhou, Guangdong, 510000, China

  • Hospital Das Clinicas Ufpe

    RECRUITING

    Recife, Pernambuco, 50670-420, Brazil

  • Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância

    RECRUITING

    Curitiba, Paraná, 80250-060, Brazil

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Hospital Universitari i Politecnic La Fe

    RECRUITING

    Valencia, 46026, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, Madrid, Comunidad de, 28034, Spain

  • Istanbul Universitesi Cerrahpasa

    RECRUITING

    Istanbul- Fatih, Istanbul, 34098, Turkey (Türkiye)

  • Kinderklinik des Uni-Klinikums Erlangen

    RECRUITING

    Erlangen, 91054, Germany

  • LMK Serviços Médicos S/S

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90480-000, Brazil

  • Local Institution - 0010

    WITHDRAWN

    São Paulo, 04022-001, Brazil

  • Local Institution - 0013

    WITHDRAWN

    Curitiba, Paraná, 80250-060, Brazil

  • Local Institution - 0017

    WITHDRAWN

    San Juan, 00917, Puerto Rico

  • Local Institution - 0020

    WITHDRAWN

    Chicago, Illinois, 60611, United States

  • Local Institution - 0023

    WITHDRAWN

    Indianapolis, Indiana, 46202, United States

  • Local Institution - 0027

    NOT_YET_RECRUITING

    Rio de Janeiro, 21941-612, Brazil

  • Local Institution - 0032

    WITHDRAWN

    Cuiabá, Mato Grosso, 78020-500, Brazil

  • Local Institution - 0033

    WITHDRAWN

    Porto Alegre, Rio Grande do Sul, 90020-090, Brazil

  • Local Institution - 0036

    WITHDRAWN

    Austin, Texas, 78723, United States

  • Local Institution - 0038

    WITHDRAWN

    Lancaster, California, 93534, United States

  • Local Institution - 0044

    NOT_YET_RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Local Institution - 0048

    WITHDRAWN

    Iași, Iaşi, 700135, Romania

  • Local Institution - 0049

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100045, China

  • Local Institution - 0059

    WITHDRAWN

    North New Hyde Park, New York, 11040, United States

  • Local Institution - 0061

    NOT_YET_RECRUITING

    Ankara, 06170, Turkey (Türkiye)

  • Local Institution - 0062

    WITHDRAWN

    Sofia, 1797, Bulgaria

  • Local Institution - 0065

    WITHDRAWN

    Cincinnati, Ohio, 45229, United States

  • Local Institution - 0066

    WITHDRAWN

    Cleveland, Ohio, 44109, United States

  • Local Institution - 0069

    NOT_YET_RECRUITING

    Sofia, 1309, Bulgaria

  • Local Institution - 0074

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100020, China

  • PSEG- Pesquisa Clínica

    RECRUITING

    Vila Clementino, São Paulo-SP, 04038-002, Brazil

  • Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari

    RECRUITING

    Hamburg, 22081, Germany

  • Santa Casa Instituto de Pesquisa

    RECRUITING

    São Paulo, 01223-001, Brazil

  • Santa Casa de Misericordia de Belo Horizonte

    RECRUITING

    Belo Horizonte, Minas Gerais, 30150-221, Brazil

  • Sc Medaudio-Optica Srl

    RECRUITING

    Râmnicu Vâlcea, Vâlcea County, 247065, Romania

  • Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca

    RECRUITING

    Cluj-Napoca, Cluj, 400177, Romania

  • The Children's Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400065, China

  • The Children's Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310057, China

  • The First Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130000, China

  • Umraniye Training and Research Hospital

    RECRUITING

    Istanbul, 34766, Turkey (Türkiye)

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD

    RECRUITING

    Plovdiv, 4002, Bulgaria

  • University of Naples Federico II

    RECRUITING

    Naples, Campania, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.